BERKELEY HEIGHTS, NJ - October 30, 2008
- Genta Incorporated (OTCBB: GNTA.OB) announced today that the
Company will release its financial results for the third quarter
2008 on Thursday, November 6, 2008. Genta management will
host a conference call and live audio webcast to discuss financial
results and corporate activities on that date at 8:00 am ET.
Participants can access the live call by dialing (877) 634-8606
(U.S. and Canada) or (973) 200-3973 (International). The access
code for the live call is Genta Incorporated. The call will also be
webcast live at
http://www.genta.com/investorrelation/events.html
. For investors unable to participate in the live call, a
replay will be available approximately two hours after the
completion of the call, and will be archived for 30 days. Access
numbers for this replay are: (800) 642-1687 (U.S. and Canada) and
(706) 645-9291 (International); conference ID number is
70101499.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with
cancer. Two major programs anchor the Company's research
platform: DNA/RNA-based Medicines and Small Molecules.
Genasense® (oblimersen sodium) Injection is the Company's lead
compound from its DNA/RNA Medicines program. Genta is
currently recruiting patients to the AGENDA Trial, a global Phase 3
trial of Genasense in patients with advanced melanoma. The
leading drug in Genta's Small Molecule program is Ganite® (gallium
nitrate injection), which the Company is exclusively marketing in
the U.S. for treatment of symptomatic patients with cancer-related
hypercalcemia that is resistant to hydration. The Company has
developed G4544, an oral formulation of the active ingredient in
Ganite, that has recently entered clinical trials as a potential
treatment for diseases associated with accelerated bone loss.
The Company is also developing tesetaxel, a novel, orally absorbed,
semi-synthetic taxane that is in the same drug class as paclitaxel
and docetaxel. Ganite and Genasense are available on a
"named-patient" basis in countries outside the United States.
For more information about Genta, please visit our website at:
www.genta.com.
Safe Harbor
This press release may contain forward-looking statements
with respect to business conducted by Genta Incorporated. By
their nature, forward-looking statements and forecasts involve
risks and uncertainties because they relate to events and depend
on circumstances that will occur in the future.
Forward-looking statements include, without limitation,
statements about:
-
the Company's ability to obtain necessary regulatory
approval for Genasense® from the U.S. Food and Drug
Administration ("FDA") or European Medicines Agency
("EMEA");
-
the safety and efficacy of the Company's products or
product candidates;
-
the Company's assessment of its clinical trials;
-
the commencement and completion of clinical trials;
-
the Company's ability to develop, manufacture, license and
sell its products or product candidates;
-
the Company's ability to enter into and successfully
execute license and collaborative agreements, if any;
-
the adequacy of the Company's capital resources and cash
flow projections, the Company's ability to obtain sufficient
financing to maintain the Company's planned operations, or the
Company's risk of bankruptcy;
-
the adequacy of the Company's patents and proprietary
rights;
-
the impact of litigation that has been brought against the
Company; and
-
the other risks described under Certain Risks and
Uncertainties Related to the Company's Business, as contained
in the Company's Annual Report on Form 10-K and Quarterly
Report on Form 10-Q.
The Company does not undertake to update any forward-looking
statements. There are a number of factors that could cause
actual results and developments to differ materially. For a
discussion of those risks and uncertainties, please see the
Company's Annual Report on Form 10-K for 2007 and its most recent
quarterly report on Form 10-Q.
SOURCE: Genta Incorporated
CONTACT:
Genta Investor Relations
info@genta.com
908-286-3980
